How the Mighty Genomics (& Proteomics & Pharmacogenetics) Companies Have Fallen

From an interesting Nature article (subscription required) on the quickly-closing biotech IPO windows:

Companies described as working on genomics brought in almost $1 billion in the last IPO window, whereas this time not a single genomics company went public. The same applies to companies working on high-throughput screening, proteomics, microarrays and pharmacogenetics. [emphasis added]